Answers are grounded in this paper and cite their sources.
Enormous strides have been made in sequencing technology, multi-gene panels, evidence-based guidelines, and actionable results. We have been moving from reactive pharmacogenomic testing based on single gene analysis to broad pre-emptive testing, where the pharmacogenetic information is available in electronic health records and prescription systems enabling dosing decisions before a prescription is written.
No takes yet. Share an insight, caveat, or question.
Manju T. Beier (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: